Prostate Cancer Long-Term Survival No Better With Finasteride
Long-Term Survival No Better With Finasteride in Prostate CA
Finasteride is associated with a reduction in the risk of prostate cancer (PCa), but is not associated with improved survival over 18 years, according to a study published in the New England Journal of Medicine (2013:369:603-610).
Ian M. Thompson Jr., MD, of the University of Texas Health Science Center at San Antonio, and colleagues analyzed survival rates among all participants from the Prostate Cancer Prevention Trial through Oct. 31, 2011.
Of the 18,880 eligible men who underwent randomization in the trial, the researchers found that PCa was diagnosed in 10.5% of men in the finasteride group and 14.9% of men in the placebo group, which translated into a significant 30% reduction in the relative risk of PCa.
"Data from 18 years of follow-up showed that the use of finasteride over a period of seven years in a general population of men with a median age at study entry of 63.2 years reduced the risk of prostate cancer but did not significantly affect mortality," the authors write.